2,851
edits
Nicotinamide Mononucleotide (NMN): Difference between revisions
Nicotinamide Mononucleotide (NMN) (view source)
Revision as of 18:39, 11 December 2023
, 11 December 2023→MIB-626
| Line 81: | Line 81: | ||
=== MIB-626 === | === MIB-626 === | ||
[[File:MIB-626 NAD+ .png|thumb|The placebo capsules had no effect on NAD+ levels over the course of 14 days (left graph). NMN doses of 1,000 mg taken once daily doubles NAD+ levels (middle graph). When taken twice daily, NMN triples NAD+ levels (right graph).]] | [[File:MIB-626 NAD+ .png|thumb|The placebo capsules had no effect on NAD+ levels over the course of 14 days (left graph). NMN doses of 1,000 mg taken once daily doubles NAD+ levels (middle graph). When taken twice daily, NMN triples NAD+ levels (right graph).{{pmid|35182418}}]] | ||
MIB-626, developed by | MIB-626, developed by ''Metro International Biotech'', is a microcrystalline form of NMN. This formulation may offer enhanced stability, solubility, or bioavailability compared to the regular crystalline form of NMN, potentially optimizing the efficacy of NMN supplementation. MetroBiotech plans to bring MIB-626 on the market as drug, not as dietary supplement. For that reason, several clinical trials are ongoing evaluating the effects and safety of MIB-626 on humans. | ||
Early results have indicated that a dosage of 1000 mg over 14 days can raise NAD+ levels ([[Area Under the Curve (AUC)|AUClast]]) about factor 1.7, and 2000 mg can increase by factor 3.7 above baseline in overweight or obese adults.{{pmid|35182418}} | Early results have indicated that a dosage of 1000 mg over 14 days can raise NAD+ levels ([[Area Under the Curve (AUC)|AUClast]]) about factor 1.7, and 2000 mg can increase by factor 3.7 above baseline in overweight or obese adults.{{pmid|35182418}} | ||